Monopar Therapeutics Inc Market Cap ($482.67 Million)
Market Cap & Net Worth: Monopar Therapeutics Inc (MNPR)
Monopar Therapeutics Inc market cap. Monopar Therapeutics Inc (NASDAQ:MNPR) has a market capitalization of $482.67 Million ($482.67 Million) as of October 30, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #12181 globally and #3081 in its home market, demonstrating a -0.61% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Monopar Therapeutics Inc's stock price $71.91 by its total outstanding shares 6712172 (6.71 Million).
Monopar Therapeutics Inc Market Cap History (2019–2026)
Monopar Therapeutics Inc market cap history from 2019 to 2026. Data shows change from $557.11 Million to $482.67 Million (-8.52% CAGR). Check Monopar Therapeutics Inc stock quote for real-time trading data and today's change.
Index Memberships
Monopar Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.02% | #337 of 976 |
|
NASDAQ Composite
IXIC
|
$40.85 Trillion | 0.00% | #1227 of 3165 |
Weight: Monopar Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Monopar Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Monopar Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see MNPR cash flow metrics for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
1678.04x
Monopar Therapeutics Inc's market cap is 1678.04 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $205.39 Million | $122.40K | -$6.30 Million | 1678.04x | N/A |
Competitor Companies of MNPR by Market Capitalization
Companies near Monopar Therapeutics Inc in the global market cap rankings as of October 30, 2026. See how leveraged is Monopar Therapeutics Inc's balance sheet to understand what proportion of total assets are financed by equity.
Key companies related to Monopar Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #183 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #374 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #422 globally with a market cap of $67.80 Billion USD ( AU$95.82 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #498 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #183 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $540.00 |
| #374 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $818.77 |
| #422 | CSL Ltd | AU:CSL | $67.80 Billion | AU$197.50 |
| #498 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $222.76 |
Market Capitalization of Monopar Therapeutics Inc (2019–2026)
Market capitalization of Monopar Therapeutics Inc from 2019 to today. Between 2019 and today, Monopar Therapeutics Inc's market cap moved from $557.11 Million to $ 482.67 Million, with a yearly change of -8.52%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $482.67 Million | +10.12% |
| 2025 | $438.30 Million | +196.82% |
| 2024 | $147.67 Million | +1194.12% |
| 2023 | $11.41 Million | -85.65% |
| 2022 | $79.54 Million | -26.17% |
| 2021 | $107.73 Million | -47.55% |
| 2020 | $205.39 Million | -63.13% |
| 2019 | $557.11 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 30th, 2026 the market cap of Monopar Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $482.67 Million USD |
| MoneyControl | $482.67 Million USD |
| MarketWatch | $482.67 Million USD |
| marketcap.company | $482.67 Million USD |
| Reuters | $482.67 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Monopar Therapeutics Inc
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors express… Read more